Agilent appears to be successfully navigating a cyclical recovery, with revenue growth reaccelerating to 10.0% in 2026Q2 and gross margins expanding to 55.5% in 2026Q3, suggesting strong pricing power and operational leverage.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has reaccelerated from 0.8% in 2024Q4 to 10.0% in 2026Q2, while gross margins have expanded by over 300 basis points to 55.5% in 2026Q3, indicating strong pricing power and a favorable mix shift.
Agilent provides comprehensive scientific solutions that help customers achieve superior outcomes in labs, clinics, and businesses, reinforcing its market leadership.
Multiple bullish analyses highlight Agilent's potential, with strong performance indicators like a forward P/E of 20.37 and a share price of $120.96 as of April 20th.
Agilent operates worldwide, offering instruments, software, and services, supported by trade shows, conferences, and webinars to engage customers and drive adoption.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 26, 2026 | $1.62+8.7% vs $1.49 | $1.9B+2.0% vs $1.8B |
Q2 2026 May 27, 2026 | $1.49+5.7% vs $1.41 | $1.8B+2.0% vs $1.8B |
Q1 2026 Feb 25, 2026 | $1.36-0.7% vs $1.37 | $1.8B-0.5% vs $1.8B |
Q4 2025 Nov 24, 2025 | $1.59+0.4% vs $1.58 | $1.8B+0.4% vs $1.8B |
Boston Trust Walden Corp decreased its position in shares of Agilent Technologies, Inc. (NYSE: A) by 20.7% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 148,815 shares of the medical research company's stock after selling 38,915 shares
Agilent Technologies gears up for Q4 fiscal 2026 earnings, with revenues and EPS growth expected amid strength in chromatography, spectroscopy and consumables.
Jim Cramer just declared the companies that supply drug labs and research instruments the true heirs to the data center trade, and three stocks are already beating the NASDAQ-100 by a wide margin this year.
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the successful completion of its previously announced acquisition of Proscia®, a leading provider of digital-pathology software for clinical and life-sciences customers. Under the terms of the transaction, Agilent acquired Proscia for $240 million in cash at closing, with up to an additional $30 million payable based on the achievement of future performance milestones. Following the closing of the transact.
Benchmark A against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Agilent Technologies, Inc. (A)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $174.76 | $49.36B | 34.35 | 6.73% | 19.53% | 20.47% | 0.57% | |
| $457.60 | $34.22B | 459.62 | 6.99% | 1.75% | 0.81% | — | |
| $694.76 | $258.19B | 36.39 | 3.91% | 14.96% | 13.3% | 0.24% | |
| $230.25 | $161.86B | 37.58 | 2.9% | 16.91% | 8.18% | 0.54% | |
| $61.31 | $9.33B | -75.77 | 2.08% | -3.51% | -5.05% | 0.24% | |
| $1722.15 | $34.8B | 36.91 | 3.98% | 22.25% | 14966.09% | — |
Agilent Technologies, Inc. (A) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Agilent Technologies, Inc. (A) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 26, 2026·SEC
May 27, 2026·SEC
May 4, 2026·SEC
Get notified when A posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Agilent Technologies, Inc. (A) stock FAQ — growth, dividends, profitability & financials explained
Agilent Technologies, Inc. (A) reported $7.37B in revenue over the trailing twelve months. Revenue was $6.95B in fiscal year 2025. That is 13% less than the $7.95B of fiscal year 1998.
Agilent Technologies, Inc. (A) grew revenue by 8.6% over the trailing twelve months, compared with the twelve months before.
Yes. Agilent Technologies, Inc. (A) earned $1.44B in net income over the trailing twelve months (a 19.5% net margin).
Yes. Agilent Technologies, Inc. (A) pays a dividend that yields 0.57% at the current price, a small yield.
Agilent Technologies, Inc. (A) had a return on equity (ROE) of 20.5% over the trailing twelve months. That is well above the market's typical 10-15%.
Agilent Technologies, Inc. (A) generated $1.44B in free cash flow over the trailing twelve months.
